84 related articles for article (PubMed ID: 8333749)
1. [Pharmacokinetics of MX2, a new morpholino anthracycline, in CSF following intravenous injection].
Yamamoto H; Arita N; Ohnishi T; Hiraga S; Izumoto S; Taki T; Higuchi M; Hayakawa T; Shinkai H
Gan To Kagaku Ryoho; 1993 Jul; 20(9):1227-30. PubMed ID: 8333749
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
Kiya K; Ogasawara H; Fujita H; Sugiyama K; Kurisu K; Kawamoto K; Uozumi T; Shinkai H
Gan To Kagaku Ryoho; 1993 Apr; 20(5):631-5. PubMed ID: 8470921
[TBL] [Abstract][Full Text] [Related]
3. [Distribution and acute toxicity of a new morpholinoanthracycline, MX2, in normal rat brain after intra-arterial injection].
Izumoto S; Arita N; Hayakawa T; Ohnishi T; Hiraga S; Taki T; Yamamoto H
Gan To Kagaku Ryoho; 1991 Mar; 18(3):371-5. PubMed ID: 2003739
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
Cancer Chemother Pharmacol; 1997; 40(3):202-8. PubMed ID: 9219502
[TBL] [Abstract][Full Text] [Related]
5. Effect of MX2, a new morpholino anthracycline, against experimental brain tumors.
Izumoto S; Arita N; Hayakawa T; Ohnishi T; Taki T; Yamamoto H; Ushio Y
Anticancer Res; 1990; 10(3):735-9. PubMed ID: 2369088
[TBL] [Abstract][Full Text] [Related]
6. Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease.
Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
Cancer Chemother Pharmacol; 1998; 41(5):423-6. PubMed ID: 9523740
[TBL] [Abstract][Full Text] [Related]
7. [Antitumor effect of a new anthracycline derivative, MX2, against human glioma cells].
Kuratsu J; Mihara Y; Kochi M; Takaki S; Ushio Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):399-403. PubMed ID: 2930204
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro].
Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Kitai R; Uno H; Kodera T
No To Shinkei; 1995 Oct; 47(10):969-73. PubMed ID: 7577142
[TBL] [Abstract][Full Text] [Related]
9. An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Park SJ; Kaye AH; Hill JS
J Clin Neurosci; 2000 Jan; 7(1):42-7. PubMed ID: 10847650
[TBL] [Abstract][Full Text] [Related]
10. The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution.
Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Kitai R
Neurosurgery; 1995 Sep; 37(3):471-6; discussion 476-7. PubMed ID: 7501112
[TBL] [Abstract][Full Text] [Related]
11. Penetration into and elimination from the cerebrospinal fluid of diltiazem, a calcium antagonist, in anesthetized rabbits.
Naito K; Nagao T; Otsuka M; Harigaya S; Nakajima H
Arzneimittelforschung; 1986; 36(1):25-8. PubMed ID: 3954820
[TBL] [Abstract][Full Text] [Related]
12. [Penetration of cephaloridine and cephalothin into the cerebrospinal fluid-clinical study (author's transl)].
Kano M; Ohta H; Kinjo T; Ito A
No Shinkei Geka; 1975 Apr; 3(4):305-12. PubMed ID: 1239674
[TBL] [Abstract][Full Text] [Related]
13. [Effect of MX-2, a morpholino anthracycline derivative, against human and rat glioma cells and experimental leptomeningeal tumors in rats].
Izumoto S; Arita N; Ushio Y; Hayakawa T; Ohnishi T; Taki T; Yamamoto H; Oku Y; Mogami H; Komeshima N
Gan To Kagaku Ryoho; 1988 May; 15(5):1765-9. PubMed ID: 3369870
[TBL] [Abstract][Full Text] [Related]
14. Subcellular localization and cellular pharmacokinetics of MX2, a new morpholino anthracycline in glioma cells using confocal laser scanning microscopy.
Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Arai Y; Kitai R
Neurol Res; 1994 Aug; 16(4):257-64. PubMed ID: 7984256
[TBL] [Abstract][Full Text] [Related]
15. Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys.
McGovren JP; Stewart JC; Elfring GL; Smith RB; Soares N; Wood JH; Poplack DG; Von Hoff DD
Cancer Treat Rep; 1982 Jun; 66(6):1333-41. PubMed ID: 7083237
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics of KRN 8602 in cancer patients].
Majima H; Shinkai H
Gan To Kagaku Ryoho; 1991 Dec; 18(15):2589-95. PubMed ID: 1746971
[TBL] [Abstract][Full Text] [Related]
17. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
Berg SL; Stone J; Xiao JJ; Chan KK; Nuchtern J; Dauser R; McGuffey L; Thompson P; Blaney SM
Cancer Chemother Pharmacol; 2004 Jul; 54(1):85-8. PubMed ID: 15042312
[TBL] [Abstract][Full Text] [Related]
18. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.
Hu XF; Slater A; Rischin D; Kantharidis P; Parkin JD; Zalcberg J
Br J Cancer; 1999 Feb; 79(5-6):831-7. PubMed ID: 10070877
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 and blood brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration.
Martin R; Schwuléra U; Menke G; Rudolph W; Buch K; Fasold H; Lissner R; Thrun A; Krauseneck P; Bogdahn U
Eur Cytokine Netw; 1992; 3(4):399-406. PubMed ID: 1421012
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in megakaryocytic leukemia cell lines by MX2, a morpholino anthracycline.
Katsurada T; Adachi M; Kido H; Date M; Kishimoto Y; Yamanaka Y; Kimura T; Fukuhara S
Exp Hematol; 1997 Sep; 25(10):1077-83. PubMed ID: 9293905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
